{Reference Type}: Journal Article
{Title}: Type 2 diabetes patients requiring empagliflozin in Southeast of Iran: Frequency and guideline adherence (2022-2023).
{Author}: Khoshnazar SM;Dehghani A;Bagheri F;Pezeshki S;Yousefzadeh G;
{Journal}: Hipertens Riesgo Vasc
{Volume}: 41
{Issue}: 2
{Year}: 2024 Apr-Jun 22
暂无{DOI}: 10.1016/j.hipert.2023.10.004
{Abstract}: <B>BACKGROUND: </B>Empagliflozin plays a beneficial role in individuals with type 2 diabetes at high risk of cardiovascular complications. This study aimed to assess the prevalence of individuals with type 2 diabetes who required empagliflozin based on clinical guidelines between the years 2022 and 2023.<BR><B>METHODS: </B>This study was a descriptive-analytical cross-sectional study conducted on a target population of patients with type 2 diabetes. Patient data, including demographic characteristics, smoking status, hypertension, hyperlipidemia, renal insufficiency, retinopathy, and proteinuria, were collected. The indication for prescribing empagliflozin was determined based on the risk of cardiovascular complications.<BR><B>RESULTS: </B>A total of 398 individuals with type 2 diabetes with a mean age of 58.4 years were examined. Overall, 87.4% of the patients had an indication for empagliflozin prescription. The indication for empagliflozin prescription was significantly higher in men, individuals with hyperlipidemia, those over 55 years of age, obese individuals, and smokers. The mean age, body mass index, and triglyceride levels were higher in candidates for empagliflozin prescription. Male candidates for empagliflozin had significantly higher rates of smoking and systolic blood pressure compared to females.<BR><B>CONCLUSIONS: </B>The findings of this study demonstrated that a significant percentage of individuals with type 2 diabetes had an indication for empagliflozin prescription based on clinical and laboratory criteria.